Garcia Orthodontics Sets the Bar with 4,000+ 5-Star Reviews & Modern Smile Solutions
Garcia Orthodontics, a leader in orthodontic care based in Miami, is proud to announce exciting developments that are transforming patient experiences and outcomes. With the addition of the revolutionary iTero Lumina Intraoral Scanner, a milestone achievement of over 4,000 five-star Google reviews, and a commitment to flexible financing with no credit history required, Garcia Orthodontics in Miami is redefining what it means to receive quality care with heart.
The Latest in Precision and Comfort: iTero Lumina Intraoral Scanner
Garcia Orthodontics continues to stay ahead of the curve by integrating the iTero Lumina, one of the most advanced intraoral scanners on the market. This groundbreaking technology captures exceptionally detailed 3D digital images, enabling Dr. Francisco J. Garcia to deliver personalized, efficient treatment plans with maximum comfort and minimal invasiveness. It's orthodontics reimagined—faster, more accurate, and more comfortable.
Trusted by Thousands: Over 4,000 Five-Star Google Reviews
With an extraordinary milestone of 4,000+ five-star reviews, Garcia Orthodontics has earned the trust and admiration of families throughout Miami. Patients consistently praise the team's warm, welcoming environment, outstanding customer service, and consistent results. It's not just about straight teeth—it's about smiles that radiate confidence and happiness.
Making Great Smiles Accessible: Flexible Financing Options
Understanding that financial concerns can be a barrier to care, Garcia Orthodontics proudly offers easy monthly payment plans with no credit history required. Everyone deserves a confident smile, and the team is committed to working with each family to make treatment affordable and stress-free.
A Practice That Puts People First
From the moment you walk into Garcia Orthodontics' vibrant, 5,000-square-foot office, you'll feel the difference. Equipped with advanced technologies like 3D X-rays, iTero 3D modeling, and HEPA air purification systems, the office prioritizes both innovation and safety. But it's the people who truly make the difference.
'Our team goes above and beyond every single day,' said Dr. Francisco Garcia. 'We're not just focused on orthodontics—we're focused on uplifting people. Every patient has a story and a dream, and we're honored to be part of that journey.'
With a rich family legacy in healthcare and fluency in six languages, Dr. Garcia ensures that language is never a barrier to world-class care. Whether you're visiting for braces, Invisalign, or a consultation, you'll receive tailored care designed to meet your goals—and exceed your expectations.
###
Media Contact
Dr. Garcia
Garcia Orthodontics
11400 N Kendall Dr #105, Miami, FL 33176
[email protected]
https://orthodontistmiami.com/
newsroom: news.38digitalmarket.com
Source published by Submit Press Release >> Garcia Orthodontics Sets the Bar with 4,000+ 5-Star Reviews & Modern Smile Solutions
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
2 minutes ago
- CBS News
Baltimore organizations try to keep the momentum going with overdose prevention
Some Baltimore organizations are working around the clock to combat drug abuse while trying to prevent residents from overdosing. The Pride Center of Maryland's Harm Reduction Team was in action on Wednesday in the city's Old Gaucher neighborhood, handing out resources, including Narcan. Those getting this help say this work is sorely needed, adding it's a life-or-death situation. Every day, members of the Pride Center of Maryland's Harm Reduction Team are outside the nonprofit's resource center on Maryland Avenue. They're sitting at tables, which are filled with food, hygiene products, clothes -- as well as Narcan, fentanyl strips, and other health resources. It's free for anyone who walks by. Jerome Scott, the Pride Center's program manager of wellness, said the purpose is about visibility and to let people know they are here to help. "[Let people know] we see you, we care, and we have things for you," Scott said. "We just like to let our faces be known." But, they aren't just stationary. Scott packed a few drawstring bags with what was on the tables and walked several blocks around the neighborhood, handing them out to anyone he saw. A volunteer also handed out lunches alongside him. Scott said there are times he would leave Narcan and other resources in certain locations, even if no one is there, so it can be readily accessible if someone were to use it nearby. Scott stressed that it's important this work doesn't lose momentum. "These are our brothers, these are our sisters, our aunts, our uncles out here. So, we wanna be there for them," Scott said. Scott said the mass overdoses in the Penn North neighborhood in July show why this work can't slow down. Penn North is another neighborhood where Scott does outreach and brings resources to. Jessica Collins, who received some of the Pride Center's free resources, said she's also been in an addiction treatment center since May. She said these resources need to be more accessible to encourage addicts to get help. "It's just each individual taking that step to go forward to wanting that that person making that decision to want to get help," Collins said. When asked how much Narcan his team has on hand, Scott said they try to have at least 500. However, the team goes through its inventory often, especially in the summer months.
Yahoo
29 minutes ago
- Yahoo
FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
WASHINGTON (AP) — U.S. health regulators are warning doctors and patients about safety issues with two separate Boston Scientific heart devices recently linked to injuries and deaths. The Food and Drug Administration issued two alerts Wednesday about electrical problems tied to the company's heart-zapping defibrillator systems and a separate issue with a heart implant used to reduce stroke risk. The agency said the company's Endotak Reliance defibrillator wires can become calcified, leading to failures in delivering life-saving shocks to the heart, according to the FDA. Defibrillators are surgically placed in the upper chest, where they monitor irregular heartbeats and use electrical shocks to jolt the heart back to normal. As of July 24, Boston Scientific has reported 386 serious injuries and 16 deaths associated with this issue, the agency said. Ten of the deaths were judged to be due to the device failing to function properly, the company said in an email. Four were linked to attempts to surgically remove the devices from patients and two others were deemed unrelated to the implants. Boston Scientific's wires were distributed between 2002 and 2021 and are no longer available, the company noted in its letter to doctors. Some patients will need to have the devices replaced, though physicians should weigh the risks of the removal procedure. In a separate notice, the FDA said Boston Scientific recently updated instructions for implanting its Watchman device, which closes a portion of the heart's left atrium to reduce the risk of stroke. In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the level of anesthesia for patients undergoing the initial implantation procedure. Watchman is an alternative to long-term treatment with blood thinners for patients at increased risk of stroke. As of July 30, the company has reported 120 serious injuries and 17 deaths related to the issue, the FDA said. A company investigation concluded that the safety issue 'is not associated with the design or manufacture of any component of the Watchman system. Heart devices, including defibrillators and other implants, are Boston Scientific's largest business, making up two-thirds of its $5 billion in revenue for the most recent quarter. Shares of Boston Scientific Corp. fell nearly 1.8 percent Wednesday to close at $102.95 in trading. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Yahoo
29 minutes ago
- Yahoo
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
BEDFORD, Mass., August 06, 2025--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 11:30 a.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at About Stoke TherapeuticsStoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit View source version on Contacts Stoke Media & Investor Contacts: Dawn KalmarChief Communications Officerdkalmar@ 781-303-8302 Doug SnowDirector, Communications & Investor RelationsIR@ 508-642-6485
